A member of Broadway Angels, an angel investment group, Karen has helped to launch both the Rosenman Institute’s and QB3’s Executive Mentorship program. Previously, Karen was the CEO of Redwood Bioscience which she joined as the first non-founder employee, leading the company through its successful acquisition by Catalent (CTLT). Redwood, now Catalent Biologics, continues to be a pioneer in developing therapeutic conjugate technology and antibody-drug conjugates for improving cancer treatment. Prior to joining Redwood, Karen co-founded and was a Partner with Thomas, McNerney & Partners, a health care technology-focused venture firm with $600 million under management. During her venture career, Karen was involved with 15 companies from initial investment to IPO/Acquisition; three of which she launched in collaboration with scientific Founders. She graduated Phi Beta Kappa and magna cum laude with a B.S. in Economics from the Wharton School at the University of Pennsylvania.